GENERAL INFORMATION 1. Title of Dataset: COVID-19 Vaccine Purchase Agreements 2. Author Information A. Principal Investigator Contact Information Name: Suerie Moon Institution: Global Health Centre, Graduate Institute of International and Development Studies Address: Chemin Eugène-Rigot 2A, Case postale 1672, 1211 Geneva 1, Switzerland Email: suerie.moon@graduateinstitute.ch B. Associate or Co-investigator Contact Information Name: Anna Bezruki Institution: Global Health Centre, Graduate Institute of International and Development Studies Address: Chemin Eugène-Rigot 2A, Case postale 1672, 1211 Geneva 1, Switzerland Email: anna.bezruki@graduateinstitute.ch 3. Date of data collection (single date, range, approximate date): approximate range, 2020-07-01-present 4. Information about funding sources that supported the collection of the data: Swiss National Science Foundation SHARING/ACCESS INFORMATION 1. Licenses/restrictions placed on the data: Open Access, Creative Commons and distributed in accordance with the Creative Commons Attribution Non Commercial International (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. Third party material are not included. See: https://creativecommons.org/licenses/by-nc/4.0/ 2. Recommended citation for this dataset: Global Health Centre. (2021). COVID-19 Vaccine Purchase Agreements. Graduate Institute of International and Development Studies. Retrieved from: https://www.knowledgeportalia.org/covid19-vaccine-arrangements DATA & FILE OVERVIEW 1. Data are updated every two to three weeks. METHODOLOGICAL INFORMATION 1. Description of methods used for collection/generation of data: Information on arrangements aggregated from publicly available sources, including news reports (links in dataset). Country population and income information available from the World Bank (www.data.worldbank.org), with exception of Taiwanese data, which is available from the Taiwanese government (www.eng.stat.gov.tw). Clinical trial stage information primarily based on the New York Times’ vaccine tracker (https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html). Information on vaccine approval status is based on UNICEF’s COVID-19 Vaccine Market Dashboard (https://www.unicef.org/supply/covid-19-vaccine-market-dashboard). DATA-SPECIFIC INFORMATION FOR: [COVID-19_Vaccine_Agreements] 1. Variable List: Sheet 1: Primary Arrangements . This sheet contains information on purchasing arrangements made between vaccine developers and other entities (companies, countries, multilateral organizations). Vaccine candidate: Vaccine developer name for each vaccine candidate. Developer Location: Main location/headquarters of each vaccine developer. Trial Phase: Current phase of the clinical trial - Phase 1/2, Phase 2, Phase 2/3, Phase 3, Terminated, and Approved. When a vaccine has achieved emergency or standard regulatory approval in at least one country, based on UNICEF data, it is categorized as Approved, even if clinical trials are still ongoing. 1 or 2 doses: Vaccine candidates require 1 or 2 doses, depending on the candidate. Arrangement Type: "Multilateral Purchase" denotes arrangements between multilateral entities such as COVAX or the EU with vaccine developers; "Government Purchase" tracks arrangements between a given country and vaccine developers; "Private Purchase" tracks purchases between private entities and vaccine developers; “Private Donation” tracks direct donations from vaccine developers to other entities; and "Combination" tracks combination manufacturing and purchasing arrangements. Finalized Commitment: Arrangements that appear to have been confirmed/finalized by their parties are listed as "Yes," those for which the arrangement status is unknown or conflicting information is present are listed as "Unclear", those that are in negotiations are listed as "No" and those that were finalized but have since been canceled are listed as "Terminated". Manufacturer and/or Distributor: When available, the manufacturer and/or distributor is provided. Manufacturer and/or Distributor Primary Location: The primary location/headquarters of the vaccine manufacturer and/or distributor. For arrangements where separate manufacturers and distributors are listed, only the location for the manufacturer is listed here. Doses committed: Doses committed in the arrangement, in millions. Does not include options for purchases of additional doses that are included in some contracts (these are logged, when present, in the "Notes" column). Timeline at time of arrangement: Free text tracking of proposed timeline for delivery of doses at the time of the arrangement. Price (in USD millions): The reported confirmed or estimated price of the purchase agreements, directly as reported or calculated based on reported price/dose (calculation method noted in the “Notes” column). If provided in currency other than USD, converted based on conversion rate of the day of the reporting. Price/Dose (in USD): The reported confirmed or estimated price per dose of the purchase agreements, directly as reported or calculated based on reported total price (calculation method noted in the “Notes” column). If provided in currency other than USD, converted based on conversion rate of the day of the reporting. Buyer/Recipient: Country, territory, or multilateral entity that will receive the vaccines from the arrangement. Region: Region for the buyer/recipient, as defined by the World Bank. Income Level: Income level as defined by the World Bank. Income level for African Union and European Union as if participating countries were a single entity. GNI/capita (Atlas method): For the Buyer/Recipient, based on World Bank data. GNI (Current USD in millions): For the Buyer/Recipient, based on World Bank data (Atlas method). Doses/Capita: Number of committed doses per capita of Buyer/Recipient. Proportion of population: Proportion of the population that would be covered by the doses committed (taking into account the number of doses required for each candidate). Population Size: Based on World Bank data. Population Size (in millions): Rounded population size. Notes: Free text tracking of relevant information on the arrangements. Sources: URLs for all sources used for each arrangement. Sheet 2: Secondary Arrangements. This sheet contains information on secondary purchase arrangements between entities that have already purchased vaccines and secondary entities (recipients) that are receiving these vaccines through purchase or donation. Should a vaccine developer donate doses directly, that is captured in Sheet 1. Vaccine candidate: Vaccine developer name for each vaccine candidate. Trial Phase: Current phase of the clinical trial - Phase 1/2, Phase 2, Phase 2/3, Phase 3, Terminated, and Approved. When a vaccine has achieved emergency or standard regulatory approval in at least one country, based on UNICEF data, it is categorized as Approved, even if clinical trials are still ongoing. Donor: Name of the entity donating the vaccines Finalized Commitment: Arrangements that appear to have been confirmed/finalized by their parties are listed as "Yes," those for which the arrangement status is unknown or conflicting information is present are listed as "Unclear", those that are in negotiations are listed as "No" and those that were finalized but have since been canceled as listed as "Terminated". Manufacturer: When available, the manufacturer is provided. Manufacturer Primary Location: The primary location/headquarters of the manufacturer. Recipient: Name of the entity receiving the vaccines. Doses Committed (in millions): Number of doses provided in the arrangement, in millions. 1 or 2 doses: Vaccines require 1 or 2 doses, depending on the vaccine. Timeline: Free text tracking of proposed timeline for delivery of the first batch of doses at the time of the arrangement. Provided in Month-Year. Donation/Purchased: Denotes whether the secondary arrangement is a purchase, donation, grant, exchange, or loan. Secondary or Tertiary Transfer: Denotes whether the transfer is “Secondary” or “Tertiary” transfer, where a secondary transfer is defined as one that is between an entity that has acquired vaccines from a vaccine developer and gives, sells, or exchanges the doses or the money for such doses with another entity, and a tertiary transfer is defined as one between an entity that has acquired vaccines from an entity other than a vaccine producer, and transfers them to another entity. Transfer Type: Denotes whether the secondary arrangement is direct or through an intermediary, where direct is an arrangement between the donor and recipient while intermediary includes a third entity (such as COVAX) through which the arrangement occurs. Recipient Income Level: Income level as defined by the World Bank. GNI/capita (Atlas method): For the Buyer/Recipient, based on World Bank data. GNI (Current USD in millions): For the Buyer/Recipient, based on World Bank data (Atlas method). Doses/Capita: Number of committed doses/capita of Recipient. Proportion of population: Proportion of the population that would be covered by the doses committed (taking into account number of doses required for each candidate). Population Size: Based on World Bank data. Population Size (in millions): Rounded population size. Notes: Free text tracking of relevant information on the arrangements. Sources: URLs for all sources used for each arrangement 3. Missing data codes: “Not available,” NA (as abbreviated form of Not Available), and blanks are used to signify data that is not available or not relevant.